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Abstract
Motivation: The discovery of relationships between gene expression measurements and pheno-
typic responses is hampered by both computational and statistical impediments. Conventional
statistical methods are less than ideal because they either fail to select relevant genes, pre-
dict poorly, ignore the unknown interaction structure between genes, or are computationally
intractable. Thus, the creation of new methods which can handle many expression measure-
ments on relatively small numbers of patients while also uncovering gene-gene relationships and
predicting well is desirable.
Results: We develop a new technique for using the marginal relationship between gene ex-
pression measurements and patient survival outcomes to identify a small subset of genes which
appear highly relevant for predicting survival, produce a low-dimensional embedding based on
this small subset, and amplify this embedding with information from the remaining genes. We
motivate our methodology by using gene expression measurements to predict survival time for
patients with diffuse large B-cell lymphoma, illustrate the behavior of our methodology on care-
fully constructed synthetic examples, and test it on a number of other gene expression datasets.
Our technique is computationally tractable, generally outperforms other methods, is extensible
to other phenotypes, and also identifies different genes (relative to existing methods) for possible
future study.
Key words: regression; principal components; matrix sketching; preconditioning
Availability: All of the code and data are available at https://github.com/dajmcdon/
aimer/.
1 Introduction
A typical scenario in genomics is to obtain expression measurements for thousands of genes from
microarrays or RNA-Seq which may be relevant for predicting a particular phenotype. Such studies
have been useful in relating specific genetic variations to a wide variety of outcomes such as disease
specific indicators (Barrett et al., 2008; Burton et al., 2007; Lesage and Brice, 2009; Sladek et al.,
2007); drug or vaccine response (Kennedy et al., 2012; Saito et al., 2016); and individual traits
like motion sickness (Hromatka et al., 2015) or age at menarche (Elks et al., 2010; Perry et al.,
2014).In these scenarios, researchers are interested in the accurate prediction of the phenotype and
the identification of a handful of relevant genes with a reasonable computational expense. With
these goals in mind, supervised linear regression techniques such as ridge regression (Hoerl and
Kennard, 1970), the lasso (Tibshirani, 1996), the Dantzig selector (Candes and Tao, 2007), or
other penalized methods are often employed.
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However, because phenotypes tend to be the result of groups of genes, which perhaps together
describe more complicated biomechanical processes, rather than individual polymorphisms, recent
approaches have tried to account for this group structure. Techniques such as the group lasso (Yuan
and Lin, 2006) can predict the response with sparse groupings of coefficients as long as the groups
are partially understood ahead of time. In contrast, unsupervised methods such as principal com-
ponents analysis (Hotelling, 1957; Jolliffe, 2002; Pearson, 1901) are often used directly on the genes
when no phenotype is being examined (Alter et al., 2000; Sladek et al., 2007; Wall et al., 2003).
Finally, modern approaches developed specifically for the genomics context such as supervised gene
shaving (Hastie et al., 2000), tree harvesting (Hastie et al., 2001), and supervised principal com-
ponents (Bair and Tibshirani, 2004; Bair et al., 2006) have sought to combine the presence of a
response with the structure estimation properties of eigendecompositions from unsupervised tech-
niques to obtain the best of both. It is this last set of techniques that most closely resemble the
approach we present here. We give a more detailed discussion of supervised principal components
next, before motivating our method with an example.
Notation: We will use bolded letters M to indicate matrices, capital letters to denote column
vectors, such that Mj is the j
th column of the matrix M, and lower case letters mi to denote row
vectors (a single subscript) or scalars (mij being the i, j element of M). We will use the notation
MA to mean the columns of M whose indices are in the set A and [k] = {1, . . . , k}. Finally, for
a matrix M, we write the singular value decomposition (SVD) of M = U(M)Λ(M)V(M)> and
define M† to be the Moore-Penrose inverse of M. In the case only of the design matrix X discussed
below, we will use the more compact decomposition X = UΛV>.
1.1 Supervised eigenstructure techniques
The first technique for extending unsupervised principal components analysis to the case where
a response is available is principal components regression (PCR, Hotelling, 1957; Kendall, 1965).
Instead of regressing the response on all the available covariates as in ordinary least squares (OLS),
PCR first performs an eigendecomposition of the empirical covariance matrix and then regresses
the response on the subset of principal components corresponding to the largest variances. Defining
Y ∈ Rn to be the centered response vector, and X to be the n×p centered design matrix, write the
(reduced) SVD of X as X = UΛV>. For some integer d ≤ p, the principal components regression
estimator is given as the solution to
Γ̂PCR = argmin
Γ
∥∥Y −U[d]Λ[d]Γ∥∥22 ,
which has the closed form representation
Γ̂PCR = ((U[d]Λ[d])
>U[d]Λ[d])−1(U[d]Λ[d])>Y = Λ−1[d] U
T
[d]Y.
Since this solution is in the space spanned by the principal components, it is easy to rotate the
estimate back onto the span of X: β̂PCR := V[d]Γ̂PCR = V[d]Λ
−1
[d] U
T
[d]Y . Then any elements of
β̂PCR which are identically zero imply the irrelevance of those genes for predicting the phenotype
while the columns of V>[d] can be interpreted as indicating groupings of individual genes.
Principal components regression performs well under certain conditions when we believe that
there are natural groupings of covariates (linear combinations) which are useful for predicting the
response. However, Lu (2002) and Johnstone and Lu (2009) show that the empirical singular
vectors U[d] are poor estimates of the associated population quantity (the left singular vectors of
the expected value of X) unless p/n → 0 as n → ∞. In particular, when p  n, as is common in
2
sparsity of Σ−1xx 1.0000 0.9999 0.9998 0.9995 0.9991 0.9984 0.9975 0.9963 0.9946 0.9922
% non-zero β’s 0.0162 0.0216 0.0287 0.0418 0.0618 0.0843 0.1193 0.1803 0.2645 0.3699
False Negative Rate 0.0000 0.2500 0.4340 0.6117 0.7374 0.8077 0.8641 0.9100 0.9387 0.9562
Table 1: This table shows properties of the coefficients of the linear model corresponding to 10
different estimates of the inverse covariance matrix, from complete sparsity on the left (a diagonal
matrix) to still more than 99% sparsity on the right. The second row is the number of non-zero
population regression coefficients corresponding to each inverse covariance matrix. The bottom
row shows the percentage of non-zero regression coefficients which are incorrectly ignored under
the assumption on the relationship between marginal correlations and regression coefficients.
genomics where the number of gene expression measurements is much larger than the number of
patients, PCR will suffer.
To avoid this flaw in PCR, various approaches have been proposed. Hastie et al. (2000) proposed
a method called “gene shaving” that is applicable to both supervised (given a phenotype) and
unsupervised (only gene expressions) settings. In the supervised setting, it works by computing
the first principal component and ranking the genes using a combined measure that balances the
principal component scores and the marginal relationship with the response. Those genes with
lowest combined scores are removed and the process is repeated until only one gene remains,
resulting in a nested sequence of clusters containing fewer and fewer genes. Then one chooses a
cluster along this sequence, orthogonalizes the data with respect to the genes in that cluster, and
repeats the entire process again, iterating until the desired number of clusters has been recovered.
This procedure is somewhat computationally expensive as well as requiring both the cluster sizes
and the number of clusters to be chosen.
An alternative with somewhat similar behavior is supervised principal components (SPC, Bair
and Tibshirani, 2004; Bair et al., 2006). SPC avoids the high-dimensional regression problem by
first selecting a much smaller subset of useful genes which have high marginal correlation with the
phenotype (in contrast to gene shaving, which uses the marginal correlation and the covariance
between genes). By screening out most of the hopefully irrelevant genes, we can return to the
scenario where p < n. In follow-up work, Paul et al. (2008) show that, if a small marginal correlation
with the response implies irrelevance for prediction, then SPC will find any truly relevant genes
and predict the phenotype accurately. They also suggest using lasso or forward stepwise selection
after SPC to further reduce the number of genes. However, if some genes have small marginal
relationship with the response but large conditional relationship, they will be erroneously ignored
by SPC. It is this last property that our method attempts to correct. We now illustrate that the
screening step of SPC is likely to remove important genes in typical applications before discussing
how our procedure avoids suffering the same fate.
1.2 A motivating example
To motivate our methodology in relation to previous approaches, we examine a dataset consisting
of 240 patients with diffuse large B-cell lymphoma (DLBCL, Rosenwald et al., 2002) in some detail.
Each patient is measured on 7399 genes, and her survival time is recorded. Previous approaches
rely on the assumption that a small marginal correlation between the response variable, in this case
patient survival time, and the vector of expression measurements for a particular gene is sufficient
for guaranteeing the irrelevance of that particular gene for prediction. To make this assumption
mathematically precise, suppose y = x>β+, where y is the response, x is a vector of gene expression
measurements, and  is a mean-zero error. Then, the assumption can be stated mathematically
3
Figure 1: A sparse estimate of the inverse covariance of gene expression measurements for the first
250 genes from the DLBCL dataset. The estimate has 97.5% of the off-diagonal elements equal to
0. Darker colors represent inverse covariances of larger magnitude.
as Cov(xj , y) = 0 ⇒ βj = 0. While reasonable under some conditions, this assumption is perhaps
too strong for many gene expression datasets. Very often, individual gene expressions are only
predictive of phenotype in the presence of other genes. We can rewrite this assumption using the
population covariance matrix between genes, Cov(x, x) = Σxx, and the vector-valued covariance
between gene expressions and phenotype, Cov(x, y) = Σxy. Then, using the population equation
for β allows us to rewrite the assumption as
(Σxy)j = 0⇒ βj = (Σ−1xxΣxy)j = 0. (1)
In words, we are assuming that the dot product of the jth row of the inverse covariance matrix
with the covariance between x and y is zero whenever the jth element of Σxy is zero.
To examine whether this assumption holds, we can estimate both Σ−1xx and Σxy using the
DLBCL data and imagine that these estimates are the population quantities for illustration. To
estimate Σxy, we use the standard covariance estimate, but set all but the largest 120 values equal
to zero, corresponding to a sparse solution. For the case of Σ−1xx , estimating large inverse covariance
matrices accurately is impossible when p n unless we assume some additional structure. If most
of the entries are 0 (a necessary condition for (1) to hold), methods like the graphical lasso (glasso,
Friedman et al., 2008) or graph estimation (Meinshausen and Bu¨hlmann, 2006) have been shown to
work well. We use the graph estimation technique for all 7399 genes in the dataset at ten different
sparsity levels ranging from 100% to 99.2%. For visualization purposes, Figure 1 shows the first
250 genes for one estimate of the inverse covariance that is 97.5% sparse.
To assess the validity of (1), Table 1 shows the sparsity of the full inverse covariance matrix, the
percentage of non-zero regression coefficients, and the percentage of non-zero regression coefficients
which are incorrectly ignored by the assumption (the false negative rate). In all cases, Σxy is about
98% sparse. Even with an extremely sparse inverse covariance matrix, the false negative rate is at
least 25% meaning that 25% of possibly relevant genes are ignored by the analysis. If the sparsity
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of Σ−1xx is allowed to increase only slightly, the false negative rate increases to over 95%.
1.3 Our contribution
For a similar computational budget, our method outperforms existing approaches by taking advan-
tage of all the data. Our method does not require that the set of non-zero regression coefficients
be a subset of the non-zero marginal correlations.
Suppose that M ∈ Rp×p is a symmetric, nonnegative definite matrix; that is, for all vectors
a ∈ Rp, a>Ma ≥ 0 and M> = M. To approximate the matrix M, we fix an integer `  p
and form a sketching matrix S ∈ Rp×`. Then, we report the following approximation: M ≈
(MS)(S>MS)†(MS)>. The details behind the formation of the matrix S control the type of
approximation.
In the simplest case, which we employ here, we take S = piτ, where pi ∈ Rp×p is a permutation
of the identity matrix and τ = [I`,0]
> ∈ Rp×` is a truncation matrix. While many alternative
sketching matrices, mostly based on random projections, have been proposed, this method is the
only one necessary to develop our results. Without loss of generality, divide the matrix M into
blocks
M =
[
M11 M
>
21
M21 M22
]
so that we can (implicitly) construct the matrix F(M) ∈ Rp×` as
F(M) := MS =
[
M11
M21
]
.
Because
M ≈ (MS)(S>MS)†(MS)> = F(M)(S>MS)†F(M)>,
we can approximate the eigendecomposition of M using the SVD of F(M). If we decompose F =
U(F)Λ(F)V(F)>, where we have suppressed the dependence of F on M when F is an argument for
clarity, then the resulting approximation to the eigenvectors of M is V(M) ≈ FV(F)Λ(F)† = U(F).
Likewise, the approximate eigenvalues of M are given the singular values Λ(F).
Homrighausen and McDonald (2016) show that this approximation is more accurate than the
one based on M11 for performing a principal components analysis. As previous techniques for
principal components regression (like SPC) are based on M11 rather than F, it is possible that by
using F, we will have better results. As we will see, this intuition turns out to be true under some
conditions which were suggested in Section 1.2. In particular, for essentially the same computa-
tional budget, our procedure outperforms previous procedures if some genes have small marginal
correlations with the phenotype but are, nonetheless, important for predicting the phenotype con-
ditional on the presence of other genes. Furthermore, even if the assumption in (1) is true, our
procedure is not much worse than existing approaches.
In Section 2, we discuss exactly how to implement our methodology. We examine the behavior
of our procedure in Section 3. In Section 3.1, we state an explicit model for the data-generating
mechanism in order to be clear about the conditions under which our procedure works well. Sec-
tion 3.2 uses a number of carefully constructed simulations to show when our technique works well,
and when it doesn’t. In Section 4, we examine our procedure on four genetics datasets, including
the one discussed above. We find that our methods slightly outperform existing techniques on three
of them, suggesting that the motivation is sound. Finally, in Section 5, we give conclusions and
discuss some avenues for future work.
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2 Methods and computations
We now give the details of our methodology. For clarity, we assume that the design matrix X and the
response Y are already centered. Let T be a p-dimensional vector denoting standardized regression
coefficient estimates, i.e. for any j ∈ {1, 2, . . . , p}, tj is the coefficient estimate of standardized
univariate regression between response Y and covariate Xj . We use standardized regression so
that the coefficient estimates are comparable across disparate covariates. Note that tj is also the
marginal correlation between the response Y and covariate Xj .
For some threshold t∗, we separate X into two matrices XA and XAc , where A = {j : |tj | > t∗}.
We assume |A| = `. The hope is that XA contains many of the genes that are most predictive
of the phenotype under study. Ideally, high marginal correlations will suggest relevant predictors
to be emphasized in the decomposition, but unlike other methods, we will also use those genes
in the set Ac. We now focus on Xnew = [XA, XAc ] and note that it has the same range as X.
Therefore, we will use the approximation technique discussed in Section 1.3 to try to estimate the
eigendecomposition of Σxx using sample quantities. Because X
>
newXnew is symmetric and positive
definite, write
F = X>newXA =
(
X>AXA
X>AcXA
)
,
and decompose F = U(F)Λ(F)V(F). For some integer d ∈ {1, . . . , `}, we define
V̂[d] = U[d](F),
Λ̂[d] = Λ[d](F)
1/2, and
Û[d] = XnewV̂[d]Λ̂
−1
[d] .
Now we have estimates for the principal components Û[d]Λ̂[d]. Therefore, just as with princi-
pal components regression, we can regress Y on the estimated principal components to produce
estimated coefficients in principal component space:
Γ̂AIMER = argmin
Γ
∥∥∥Y − Û[d]Λ̂[d]Γ∥∥∥2
2
= Λ̂
−1
[d] Û
T
[d]Y.
Then the coefficient estimates for linear regression in the space spanned by Xnew are given by
β̂AIMER = V̂[d]Γ̂AIMER = V̂[d]Λ̂
−1
[d] Û
T
[d]Y. (2)
Because our methodology uses marginal regression to select a small number of hopefully relevant
predictors before “amplifying” their eigenstructure information with the F matrix, we refer to our
technique as “Amplified, Initially Marginal, Eigenvector Regression” (AIMER).
Unlike previous approaches, the solution given by (2) is not sparse: with probability 1, (β̂AIMER)j 6=
0, ∀j. However, most of the coefficients will be small. We therefore threshold the estimates to
produce our final estimator:
β̂AIMER(b) := β̂AIMER1(b,∞)(|β̂AIMER|), (3)
where b ≥ 0, and 1A(w) is the indicator function, which returns the value one for every element
of w ∈ A and zero otherwise. We summarize this procedure in Algorithm 1. As with SPC, the
computational burden of our method is dominated by the SVD. We use an SVD of F while SPC
uses the SVD of XA. However, since the SVD is cubic in the smaller dimension, in both cases
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Algorithm 1: Amplified, Initially Marginal, Eigenvector Regression (AIMER)
Input: centered design matrix X, centered response Y , thresholds t∗, b∗ ≥ 0, integer d
1 Compute marginal correlation tj between Xj and Y for all j;
2 Set A = {j : |tj | > t∗};
3 Set Xnew = [XA, XAc ];
4 Define F = X>newXA;
5 Decompose F = U(F)Λ(F)V(F)>;
6 Set V̂[d] = U[d](F);
7 Set Λ̂[d] = Λ[d](F)
1/2;
8 Set Û[d] = XnewV̂[d]Λ̂
−1
[d] ;
9 Calculate β̂ = V̂[d]Λ̂
−1
[d] Û
T
[d]Y ;
10 Set β̂(b∗) := β̂1(b∗,∞)(|β̂|);
Output: coefficient estimates β̂(b∗)
Simulation 1 2 3
True # 15 10 10
SPC 50 (0) 50 (0) 50 (0)
SPC+lasso 31 (9.011) 39 (3.636) 46 (2.665)
AIMER(b = 0) 1000 (0) 1000 (0) 1000 (0)
AIMER 39 (9.225) 21 (12.750) 16 (7.558)
Table 2: Average final number of predictive genes in Simulations 1, 2, and 3. The standard deviation
is shown in parentheses.
the computation is O(|A|3). Thus, to leading order, both methods require the same amount of
computation.
To make predictions given a new observation x∗, we simply center it using the mean of the
original data, reorder its entries to conform to Xnew, multiply by the coefficient vector in (3), and
add the mean of the original response vector.
3 Experimental analysis
To examine the performance of our method, we set up a number of carefully constructed simulations
under various conditions. We first discuss the generic data model we assume, a latent factor model,
which is amenable to analysis via SPC or AIMER.
3.1 Data model
Consider the multivariate Gaussian linear regression model
y = x>β + σ1 (4)
with y the response, x ∈ Rp a column vector of gene expression measurements, β = (β1, · · · , βp)>
the coefficients,  a random Gaussian distributed error with zero mean and variance 1, and σ1 > 0.
We further assume that x ∼ Np(0,Σxx) has a Gaussian distribution with mean vector 0 and
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Figure 2: Receiver operating characteristic (ROC) Curve for Simulations 1–3. The x-axis is the
false positive rate while the y-axis is the true positive rate. The curves present averages across 100
replications. SPC is limited to only 50 selected genes, and so its false positive rate is bounded.
The dashed line indicates its best case theoretical performance were it allowed to continue to select
further genes.
covariance matrix Σxx. We will assume that β is sparse, in that most of its elements are exactly 0
indicating no linear relationship between the associated gene and the response. Finally, the design
matrix X and the response vector Y include n independent observations of x and y respectively.
Model for X. As Σxx is symmetric and positive (semi-) definite, we can decompose it as
Σxx = V(Σxx)L(Σxx)V
T (Σxx)
=
(
V1 · · · Vp
)l1 0. . .
0 lp

V
>
1
...
V >p
 ,
where V1, · · · , Vp are orthonormal eigenvectors on Rp and l1 ≥ · · · ≥ lp ≥ 0 are eigenvalues. We
assume that there is some 1 ≤ G ≤ p such that the eigenvalues can be seperated into two groups,
one of which includes relatively large eigenvalues and the other relatively small eigenvalues, that
is, lk = λk + σ
2
0 for 1 ≤ k ≤ G and lk = σ20 for k > G where λ1 ≥ · · · ≥ λG > 0, and σ20 > 0.
Then, because X is multivariate Gaussian, we can write X as
X = UGΛGV
T
G + σ0E
=
(
U1 · · · UG
)
√
λ1 0
. . .
0
√
λG

V
>
1
...
V >G
+ σ0E
where latent factors U1, . . . , UG are independent and identically distributed (i.i.d.) Nn(0, I) vectors,
and the noise matrix E is n× p with i.i.d. N(0, 1) entries independent of U1, . . . , UG.
Model for Y . We assume that Y is a linear function of the first K ≤ G latent factors in UG plus
additive Gaussian noise: Y = UKΘ + σ1Z, where Θ is the coefficient vector, σ1 > 0 is a constant,
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Figure 3: Estimation and prediction performance of SPC and AIMER in the first three simulations.
The left panel shows the estimates of the regression coefficients, the middle panel shows the mean
squared error (MSE) of estimation for all 1000 genes, and the right panel shows prediction MSE
on the held-out data. The boxes indicate variability across 100 replications. The dashed black
horizontal lines indicate the true values of β.
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Figure 4: Prediction MSE averaged across 100 replications for each method for different numbers
of components (Simulation 4). We also allow λ1 to vary between 5 and 50.
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Figure 5: Performance of each method when we allow t∗ to be chosen by cross validation rather
than fixed to choose 50 genes (Simulation 5).
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and Z is distributed Nn(0, I), independent of X. Note that the expectation of Y is zero and that
this is a specific form of (4).
Implication of the model. Under this model for X and Y , the population marginal covariance
between each gene Xj and the response Y can be written as
Σxy =
Cov(X1, Y )...
Cov(Xp, Y )
 = VKΛKΘ. (5)
Therefore, the population ordinary least squares coefficients of regressing Y on X (β in (4)) can be
written as
β = Σ−1xxΣxy = VKL
−1
K ΛKΘ (6)
We will define the set B := {j : (Σxy)j 6= 0} and the set A := {j : βj 6= 0}. We note that for
K = 1, it is always the case that A = B. By manipulating the parameters in Θ, L, and Λ, we
can create a number of scenarios for testing AIMER against alternative methods.
3.2 Experiments
We present results under five different experiments. For each of the simulations which follow, we
generate datasets with n = 200 and p = 1000. We use half (n = 100) to estimate the model and
test our predictions on the other half. We repeat this process 100 times for each combination of
parameters. Throughout, we use σ0 =
√
.1 ≈ .3 and σ1 = .1. The matrix U is generated with i.i.d.
standard Gaussian entries, while the matrix V is constructed by hand to have the correct number
of orthogonal components.
The first experiment is designed to be favorable to AIMER. The second is designed to be
favorable to SPC. The third examines the extent to which the assumption that A = B is beneficial
to SPC over AIMER. The fourth examines the impact of using incorrect numbers of components,
while the fifth uses cross validation on all the tuning parameters.
Simulation 1: Favorable conditions for AIMER. In this simulation, we create data which
is amenable to AIMER at the expense of the conditions for SPC, that is we use B ⊂ A . We set
parameters in the data model as K = G = 3 and choose λ1 = 10, λ2 = 5, and λ3 = 1. In order to
achieve B ⊂ A , we set θ1 = θ2 = 1 and solve (5) for θ3 so that some corresponding elements of
Σxy will be zero. We make the first 15 elements of β non-zero, 5 corresponding to each of the three
principal components. Thus, the first 10 genes have non-zero population marginal correlation and
the remaining 990 have zero marginal correlation. In this scenario, SPC should find the first 10
important genes, but AIMER will find the remaining 5 important genes as well.
In order to focus on the relationship between performance and the condition B ⊂ A , we
examine the methods for a fixed computational budget and choose t∗ to select the same 50 most
predictive genes. We examine SPC, SPC with lasso, AIMER(b = 0), and AIMER. We use the first
3 principal components for regression in all the methods. For SPC with lasso and AIMER, we
choose the remaining tuning parameters via 10-fold cross-validation. We also give results for OLS
on the first 15 genes. This is the oracle estimator, the best one could hope to do with foreknowledge
of the predictive genes.
Figure 2 shows the classification performance using a receiver operating characteristic (ROC)
curve for SPC with lasso and AIMER in the left panel (the remaining panels are for the next
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two simulations). Examining the figure, it is easy to see that SPC+lasso identifies the first 10
genes easily, but AIMER is able to capture all 15 predictive genes at a low cost of false positive
identifications. A more detailed analysis is given in the first row of Figure 3. Panel 1–a shows
the ability of each method to estimate the β coefficients of three different factors. Coefficient
estimates for the 5 genes in factor 1 by AIMER are slightly more accurate, and no more variable,
than SPC+lasso. Furthermore, AIMER is better at estimating those β’s associated with factor
2, and much better at those associated with factor 3 (these are assumed zero in SPC). Panel 1–b
examines the mean square error (MSE) of estimation as the average squared difference between
the true coefficients and their estimates for all 1000 genes. The overall estimation accuracy of
AIMER(b = 0) is worse because of the inclusion of so many useless genes (it estimates all 1000),
however, by thresholding with AIMER, accuracy is improved and exceeds that of SPC with and
without lasso. In panel 1–c, we show the MSE for prediction, the average squared difference between
predicted values and the actual observations, for a test set. This MSE is smaller for AIMER than
for SPC much of the time, but the variance across simulations is large.
Simulation 2: Favorable conditions for SPC. This simulation compares the performance
of SPC and AIMER under conditions which are more favorable to SPC. In particular, we choose
parameters such that A = B. While AIMER is likely to perform worse because it will tend to
include irrelevant genes, it is not too much worse. Most of the parameters are the same as in
Simulation 1, except that K = G = 2, λ1 = 10, λ2 = 1, θ1 = θ2 = 1, and we use the first
two principal components to do regression. Therefore, 10 out of 1000 genes are truly predictive
of the response, and all 10 have non-zero marginal correlation with the response (the rest have
Σxy = 0). Looking again at Figure 2, both SPC+lasso and AIMER can identify all 10 predictive
genes at a small price of false positives. Examining Figure 3, we see that the estimation accuracy of
SPC/SPC+lasso is better than that of AIMER as expected, and the MSE of prediction for AIMER
is about twice that of SPC/SPC+lasso. The estimation MSE (panel 2–b) of AIMER is comparable
to that of SPC.
Simulation 3: Slight perturbations. In this simulation, we adjust only θ2 = 3, rather than 1
as in simulation 2, thereby maintaining the condition that A = B. However, in this case AIMER
works much better than SPC/SPC+lasso. Figures 2 and 3 show that AIMER can easily identify
all the predictive genes, has more precise coefficient estimates, and has much smaller MSE for
prediction. The reason is that, even though A = B, the marginal correlations for some predictive
genes are very small. Therefore those genes are more difficult for SPC to identify, but AIMER can
compensate.
For one further comparison, Table 8 shows the average (standard deviation in parentheses)
number of predictive genes selected in each of the first three simulations. AIMER selects the
smallest number of coefficients in most cases.
Simulation 4: Choosing the number of components. In the previous simulations, we used
the correct number of principal components, though such a choice is unlikely to be possible given
real data. In this simulation, we examine the impact choosing the number of components has on
estimation accuracy. We use similar parameter settings as Simulation 1 except with K = G = 2
rather than 3 (we maintain the condition that B ⊂ A). We then use all the methods with 1, 2,
and 3 components. We also adjust the values of λ1 in a range from 5 to 50. As we can see in
Figure 4, using two components reduces MSE for AIMER(b = 0) and AIMER across all values of
λ1 relative to using only one component, while using more than two components has little impact.
12
DLBCL Breast cancer Lung cancer AML
Methods MSE # genes d MSE # genes d MSE # genes d MSE # genes d
lasso 0.6805 20 0.6285 9 0.8159 22 1.9564 6
ridge 0.6485 7399 0.6407 4751 0.7713 7129 1.9234 6283
SPC 0.6828 41 3 0.6066 16 2 0.8344 19 3 2.4214 24 2
SPC+lasso 0.6780 31 3 0.6029 14 2 0.8436 9 4 2.3980 22 2
AIMER(b = 0) 1.1896 7399 2 2.6531 4751 1 0.9444 7129 1 12.4014 6283 1
AIMER 0.6518 28 4 0.6004 31 3 1.0203 13 1 1.8746 36 4
Table 3: The MSE on the test set, the number of selected genes, and the number of principal
components used (d if relevant), each averaged across the 10 random training-testing splits. Bolded
values indicate the best predictive performance for each type of method (with and without structure
learning) for each data set.
With only one component, SPC performs better than AIMER, likely due to smaller variance for a
similar bias, but using two or three components leads to large gains for AIMER. In practice, it is
worthwhile to try several numbers of components and use cross-validation to decide which works
best.
Simulation 5: The screening threshold. In previous simulations, we choose t∗ so that variable
screening by the marginal correlation would always select exactly 50 genes. Thus, we could compare
methods based on their ability to use the same amount of information. In reality, it may be better
to choose the threshold t∗ using cross validation. In this simulation, we use the same conditions
as in the previous simulation with λ1 = 10. It is still not appropriate to have more genes than
patients, so we allow the number of selected genes to be anything less than the number of patients
(100). We further use 10-fold cross-validation to choose the best threshold.
As shown in Figure 5, allowing t∗ to be chosen rather than fixed leads to improved results for
AIMER relative to SPC/SPC+lasso. The prediction MSE decreases and fewer genes are selected.
4 Performance on real data
We now illustrate our methods on 4 empirical datasets in genomics that record the censored survival
time and gene expression measurements from DNA microarrays of patients with 4 different types of
cancer. The first dataset comes from Rosenwald et al. (2002) and contains 240 patients with diffuse
large B-cell lymphoma (DLBCL) and 7399 genes. The second dataset has 4751 gene expression
measurements of 78 breast cancer patients (Van’t Veer et al., 2002). The third consists of 86
lung cancer patients measured on 7129 genes (Beer et al., 2002), and finally, we analyze a dataset
consisting of 116 patients with acute myeloid leukemia (AML, Bullinger et al., 2004) and 6283
genes.
Since the survival times for some patients are censored and right-skewed, we use log(survival time+
1) as the response. A Cox model would be more appropriate, but this transformation is enough to
illustrate our methodology. In order to assess our method using limited data, we randomly select
half of the data as the training set and let the rest be in the testing set, then estimate each model
using the training half and predict the held out data. We repeat this procedure for 10 random
splits and report the average error. We use 10-fold cross-validation on the training set to choose
all tuning parameters (t∗, b∗, d, and λ where appropriate), mimicking the procedure of a real data
analysis.
We apply 7 methods on each dataset: 1) PCR; 2) lasso; 3) ridge regression; 4) SPC; 5)
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SPC+lasso; 6) AIMER(b = 0); and 7) AIMER. We use the R packages pls (Mevik and Wehrens,
2007) to perform PCR and glmnet (Friedman et al., 2010) to perform lasso and ridge. For PCR,
SPC, SPC+lasso, AIMER(b = 0), and AIMER, we allow the number of components d to be chosen
between 1 and 5.
Our results are shown in Table 4. For each dataset, we show the MSE on the testing set,
the number of selected genes, and the number of principal components used (if relevant), averaged
across the 10 random training-testing splits. We do not show results for PCR because it is uniformly
awful. The results in Table 4 are largely consistent with the conclusions we derive from simulations.
AIMER and SPC+lasso tend to select a similar number of genes, though AIMER has better
prediction error on 3 of the 4 datasets. Interestingly, the genes selected by SPC+lasso, lasso, and
AIMER rarely overlap, suggesting that to identify genes for further study, one should try all three
methods. The online Supplement lists the genes identified by AIMER for each dataset. In the case
of DLBCL, we also list any previous research relating the selected genes to lymphoma.
The Lung Cancer data is rather odd in that AIMER(b = 0) has better performance than
AIMER. This anomaly is likely because, in contrast with the other datasets, the lung cancer
expression measurements have not been scaled relative to a control group. We tried two transfor-
mations using only the treatment group to approximate such a scaling, but, while the performance
of our method becomes comparable to SPC following transformations, it remains slightly worse.
Without a control group, it is difficult to explain this outcome with any certainty. A comparison of
these alternative transformations with our results in Table 4 is contained in the online Supplement.
As seen in the table, ridge regression is sometimes the best of all the methods. Previous
experience suggests that ridge regression is dominant if the genes are highly correlated or when
there is not a particularly predictive set of genes. However, the fact that ridge does not screen
out unimportant genes is a barrier to its applications in genomics. On the other hand, AIMER
approaches or exceeds the small prediction error of ridge regression while also selecting a small
number of predictive genes, making it a better candidate for solving these types of problems.
5 Discussion
High-dimensional regression methods help in predicting future survival time and identifying possibly
predictive genes for diseases. However, the large number of genes, the limited access to patients,
and the complex covariance structure between genes make the problem both computationally and
statistically difficult. In both simulations and analysis of actual gene expression datasets, AIMER
has comparable or slightly improved prediction accuracy relative to existing methods and finds
small numbers of actually predictive genes, all while having a similar computational burden. On
the other hand, there are some issues which warrant further exploration.
A major benefit of SPC is that it comes with theoretical guarantees under certain assumptions.
While our methodology is intended to work when these assumptions don’t hold, we do not yet have
comparable guarantees. However, the simulated experiments in this paper have suggested how we
might derive such results in a more general setting.
For the real data examples in this paper, we applied a simple monotonic transformation to the
response variable, however, extending our methods to Cox models, which are more appropriate,
and other generalized linear models for predicting discrete traits is highly desirable. It may also be
useful to examine other eigenstructure techniques such as Locally Linear Embeddings or Laplacian
Eigenmaps to produce non-linear predictors. Finally, using other matrix approximation techniques
may yield improved performance or be more amenable to theoretical analysis.
14
Funding
This work is supported by the National Science Foundation [grant number DMS–14-07439 to
D.J.M.].
Conflict of interest: none to declare.
A Genes identified for the DLBCL data
In this supplement, we perform AIMER on all four datasets (DLBCL (Rosenwald et al., 2002),
breast cancer (Bullinger et al., 2004), lung cancer (Beer et al., 2002), AML (Van’t Veer et al.,
2002)) discussed in the manuscript. Rather than using training sets containing 50% of the data as
in the main paper, we use all the observations here. We allow our method to select up to as many
features as there are observations.
A.1 DLBCL
For the DLBCL data, we not only list the selected genes, but also attempt to find any discussion of
those genes in existing literature. Our final estimated model uses 49 gene features, which correspond
to 26 genes. To examine the relevance of each selected gene for DLBCL, we adopt two approaches.
The first endeavors to find literature examining the biological connection of the identified gene
to any type of lymphoma. The second lists any reference in the (rather lengthy) methodological
literature in statistics, computer science, and bioinformatics that uses statistical or machine learning
methods to examine the DLBCL dataset.
We display our findings for all 26 genes in Table 4. To summarize, 16 out of the 26 genes have
been related to lymphoma in the biological literature, and 19 of them have already been identified
via statistical techniques developed for the DLBCL dataset. While many of the 26 genes have been
previously connected to lymphoma in general and DLBCL in particular, AIMER does identify
4 genes with symbols ALDH2, CELF2, COL16A1, and DHRS9 that have not been previously
identified in the biological or methodological literature. We note that, while we have made every
effort to locate each gene, given the large and evolving literature on this topic, those we have been
unable to locate may have none-the-less been previously studied.
A.2 Genes identified for breast cancer, lung cancer and AML data
As before, we allow the maximum number of selected genes be the same as the total number of
patients. AIMER identifies 78 genes with breast cancer data, 12 genes for lung cancer, and 50
genes for the AML dataset. We list the top 20 selected genes for breast cancer in Table 5, all 12
selected genes for lung cancer in Table 6, and the top 20 selected genes for AML in Table 7.
B Alternative analysis for lung cancer data
Compared with the other three datasets, the public lung cancer data comes presents gene expression
measurements for only patients who have been diagnosed with lung cancer. The other three datasets
instead give the logarithm of the ratio between diseased sample expression measurements and a
reference control group. To try to make the lung cancer dataset comparable to the others, we
perform two separate transformations on the data. The first transformation is to take the base-2
logarithm of all the expression measurements. Because some measurements are negative, before
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Symbol In biology Source(s) In methodology Source(s) Name of gene
1 ALDH2 × × aldehyde dehydrogenase 2 family (mitochondrial)
2 BCL2 X Blenk et al. (2007); Kramer et al. (1996) X Blenk et al. (2007); Lossos et al. (2004) BCL2, apoptosis regulator
3 CCND2 X Blenk et al. (2007) X Blenk et al. (2007); Lossos et al. (2004); Miyazaki et al. (2008) cyclin D2
4 CELF2 × × CUGBP Elav-like family member 2
5 COL3A1 X Blenk et al. (2007); Rosenwald et al. (2002) X Blenk et al. (2007) collagen type III alpha 1 chain
6 COL16A1 × × collagen type XVI alpha 1 chain
7 CR2 × X Ma and Huang (2007); Miyazaki et al. (2008) complement C3d receptor 2
8 CYP27A1 × X Zhao and Wang (2010) cytochrome P450 family 27 subfamily A member 1
9 DHRS9 × × dehydrogenase/reductase 9
10 EPHB1 X Asmar et al. (2013) X Zhao and Wang (2010) EPH receptor B1
11 ESTs X Rosenwald et al. (2002) X Liu et al. (2010) ESTs
12 FN1 X Blenk et al. (2007); Rosenwald et al. (2002) X Blenk et al. (2007); Lossos et al. (2004) fibronectin 1
13 FUT8 × X Li et al. (2015) fucosyltransferase 8
14 IGHM × X Blenk et al. (2007); Miyazaki et al. (2008); Zhao and Wang (2010) immunoglobulin heavy constant mu
15 IGKC × X Miyazaki et al. (2008); Zhao and Wang (2010) immunoglobulin kappa constant
16 IRF4 X Alizadeh et al. (2000); Radivojac et al. (2008) X Blenk et al. (2007); Li et al. (2015) interferon regulatory factor 4
17 KIAA0233 X Blenk et al. (2007); Rosenwald et al. (2002) X Blenk et al. (2007) KIAA0233 gene product
18 LMO2 X Alizadeh et al. (2000); Natkunam et al. (2007) X Blenk et al. (2007); Liu et al. (2010); Lossos et al. (2004) LIM domain only 2
19 MAPK10 X Ying and Gao (2010) X Blenk et al. (2007); Liu et al. (2010); Zhao and Wang (2010) mitogen-activated protein kinase 10
20 MME × X Blenk et al. (2007) membrane metalloendopeptidase
21 MMP2 X Gouda et al. (2014) X Ma and Huang (2007) matrix metallopeptidase 2
22 MMP7 X Matsumoto et al. (2008) × matrix metallopeptidase 7
23 MMP9 X Alizadeh et al. (2000); Sakata et al. (2004) X Liu et al. (2010) matrix metallopeptidase 9
24 MYB X Dai et al. (2016) X Blenk et al. (2007) MYB proto-oncogene, transcription factor
25 SPARC X Brandt et al. (2013); Meyer et al. (2011) × secreted protein acidic and cysteine rich
26 VPREB3 X Rodig et al. (2010) × V-set pre-B cell surrogate light chain 3
Table 4: DLBCL Predictive Genes. AIMER selected 26 genes. We note that while we have made
every effort to locate all 26 genes in the literature, a × should be taken to indicate that we were
unable to locate a reference for that gene rather than the stronger conclusion that no one has yet
investigated it.
Gene
1 Contig47405 RC
2 NM 002964
3 NM 002965
4 NM 005980
5 Contig43983 RC
6 NM 017422
7 NM 002963
8 NM 020974
9 Contig50360 RC
10 Contig55725 RC
11 NM 018265
12 NM 006115
13 AK001423
14 NM 004525
15 Contig38438 RC
16 AL050227
17 NM 014479
18 NM 002421
19 NM 000266
20 NM 006419
Table 5: Top 20 selected genes for breast cancer dataset by AIMER.
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Gene
1 D49824 s at
2 X57809 s at
3 M17886 at
4 S71043 rna1 s at
5 M87789 s at
6 V00594 s at
7 X98482 r at
8 M34516 at
9 hum alu at
10 HG2873-HT3017 at
11 HG3364-HT3541 at
12 HG3549-HT3751 at
Table 6: 12 selected genes for lung cancer dataset by AIMER.
Gene
1 112298 MSLN mesothelin
2 111553 GAGED2 G antigen, family D, 2
3 117339 APOC2 apolipoprotein C-II
4 330384 SERPINF1 serine (or cysteine) proteinase inhibitor, clade F (alpha-2
antiplasmin, pigment epithelium derived factor), member 1
5 330504 TRG@ T cell receptor gamma locus
6 220502 TCF4 transcription factor 4
7 101316 HLA-DRB3 major histocompatibility complex, class II, DR beta 3
8 109247 TRG@ T cell receptor gamma locus
9 98472 KIAA0476 KIAA0476 gene product
10 331153 HLA-DRB3 major histocompatibility complex, class II, DR beta 3
11 313178 KIAA1165 likely ortholog of mouse Nedd4 WW domain-binding pro-
tein 5A
12 330849 HLA-DRB3 major histocompatibility complex, class II, DR beta 3
13 107072 NCF4 **neutrophil cytosolic factor 4, 40kDa
14 114151 HLA-DRB3 major histocompatibility complex, class II, DR beta 3
15 246144 ESTs Highly similar to CAMP-DEPENDENT PROTEIN KINASE
INHIB
16 103236 TRG@ T cell receptor gamma locus
17 118267 SDPR serum deprivation response (phosphatidylserine binding pro-
tein)
18 114582 HLA-DPB1 major histocompatibility complex, class II, DP beta 1
19 309986 THY1 Thy-1 cell surface antigen
20 119834 LPHH1 latrophilin 1
Table 7: Top 20 selected genes for AML dataset by AIMER.
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original dataset log2 transformation normalization
Methods MSE # genes d MSE # genes d MSE # genes d
lasso 0.8159 22 0.8722 16 0.7921 20
ridge 0.7713 7129 0.7594 7129 0.7687 7129
SPC 0.8344 19 3 0.8268 32 5 0.7799 22 3
SPC+lasso 0.8436 9 4 0.8376 25 4 0.7864 19 3
AIMER(b = 0) 0.9444 7129 1 0.9570 7129 1 4.5202 7129 3
AIMER 1.0203 13 1 0.8901 13 2 0.8244 42 4
Table 8: The MSE on the test set, the number of selected genes, and the number of principal
components used (d if relevant), each averaged across the 10 random training-testing splits on the
three datasets respectively.
taking the logarithm, we first add the negative of the minimum value plus one to each feature
vector, making all measurements at least 1. This transformation mimics the standard process. The
second transformation orthonormalizes the gene expression matrix.
We use the same training and testing procedure as in the main paper on the original dataset
and the two transformed datasets. Table 8 shows the corresponding prediction MSE, the number
of selected genes, and the number of components used (when necessary) averaged over 10 training-
testing splits. It turns out that both the log2 transformation and normalization improves AIMER
relative to the other methods. The number of components used in AIMER also increases. The
number of selected genes for AIMER on the log2 transformed dataset is the same as with the
original dataset, but AIMER selects more genes on the normalized dataset. However, even after
these two transformations, AIMER is still not quite as accurate as SPC. We posit that using the
conventional transformation with a control group may enhance the results for AIMER.
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